Fiona Stanley Hospital

Blooms The Chemist implements booking platform Pharmacy chain Blooms The Chemist has adopted Healthengine's booking platform to streamline appointment management and enhance scheduling. It now allows customers to book pharmacy services, including vaccinations, via Healthengine round the clock and with real-time availability. The booking platform also features voucher management and consult room service setups, which also integrate with the pharmacy chain's system. In August, Healthengine integrated with Core Practice 's dental practice management software, allowing the latter's users to make their appointments visible via the booking platform directly. Healthengine recently introduced a new waitlist functionality on its platform, providing consumers with the ability to add themselves to an online waitlist and allowing practices to turn cancellations into appointments. VVED patient portal goes live Northern Health has recently introduced a new patient registration portal for the Victoria Virtual Emergency Department (VVED). The said portal, which went live in August, includes a comprehensive dashboard for registering patients into EMR systems, said Northern Health, a major healthcare provider in Melbourne. Developed in-house by the organisation's Digital Health team, the patient portal has enabled a "faster" registration process by enhancing data capture and validation. "In its first 15 days, the portal assisted in the reduction of duplicate patient records by 10% and increased Medicare number capture compliance from 73% to 88%," shared HIS Manager Nicholas Caruana. Anthony Gust, executive director of Northern Health's digital health division, disclosed that they plan to "reuse" the portal for residential-in-reach and outpatients. Early this year, it was announced that the VVED will double its capacity , targeting to accommodate over a thousand patients per day, with new state funding. Peninsula Health to roll out cancer IMS Peninsula Health, another healthcare provider in Melbourne, has recently digitised medication management in oncology. It will be rolling out an oncology information management system provided by Magentus, doing away with the current paper-based workflow. Peninsula Health's cancer service receives over 400 referrals each year. It hopes to improve patient safety and free up more staff time by implementing the IMS, which also directly integrates with its existing systems and My Health Record. About 250 users across the service will be utilising the system, Peninsula Health said in a statement. The same cancer IMS was also rolled out at Fiona Stanley Hospital in Western Australia in June as part of a broader contract to deploy the solution across South Metropolitan Health Service . Over a year ago, the private Catholic healthcare group St John of God Health Care signed a deal to implement the Magentus solution in its hospitals nationwide.

SOUTH SAN FRANCISCO, Calif., Sept. 2, 2024 /PRNewswire/ -- IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to address IgE-mediated diseases, presented exciting data on the company's lead candidate, IGNX001, an IgG4 monoclonal antibody-based therapeutic for peanut allergy. These data were presented during the 2024 Annual Conference of the Australasian Society of Clinical Immunology and Allergy (ASCIA), taking place in Adelaide, Australia from September 3-6, 2024. Highlights from ASCIA Michael O'Sullivan, MBBS, FRACP, FRCPA, lead investigator, presented information on IgGenix's Phase 1 human clinical trial in peanut allergy "ACCELERATE Peanut." This study, which is active and screening, will evaluate the safety and tolerability of IGNX001, a therapeutic candidate which aims to offer the potential of rapid protection for peanut allergic patients. Derek Croote PhD, chief technology officer and co-founder of IgGenix, presented preclinical data on IGNX001 demonstrating robust protection against peanut-mediated mast cell activation, as well as against anaphylaxis in a murine model of peanut allergy. The complete preclinical findings were recently published in The Journal of Allergy and Clinical Immunology. "IGNX001 marks a potentially major step forward in treating peanut allergies," said Michael O'Sullivan, MBBS, FRACP, FRCPA, Consultant Clinical Immunologist at Fiona Stanley Hospital and Perth Children's Hospital, and Clinical Senior Lecturer at the University of Western Australia. "By using cutting edge research to re-engineer harmful IgE antibodies to IgG4 blocking antibodies that bind to allergens without causing reactions, this approach offers the potential for a faster, more effective alternative to current therapies. It has the potential to help change peanut allergy management, reducing severe reaction risks and improving quality of life for millions worldwide." Oral Presentation Title: Accelerating Towards Treatment Options for Adolescents and Adults With Peanut Allergy: Phase 1 Trial of Peanut-Specific Igg4 Antibody Therapeutic (IGNX001) Presenter: Michael O'Sullivan, MBBS, FRACP, FRCPA Poster Presentation Title: Preclinical Activity and GLP Safety Toxicology Data Ahead of Phase 1 Initiation of IGNX001 in Peanut Allergy Presenter: Derek Croote, PhD The abstracts can be accessed here. About IgGenix IgGenix is a privately held antibody discovery and development company taking a revolutionary approach to directly address allergies and atopic diseases. Through our proprietary SEQ SIFTER™ discovery platform, developed from foundational research of co-founders Stephen Quake, Kari Nadeau, and Derek Croote of Stanford University, we isolate and re-engineer fully human, high-affinity, allergen-specific antibodies designed to block and prevent the allergic cascade. By targeting common immunodominant allergens and their most important epitopes across the patient population, we intend to treat allergic pediatric and adult patients alike across food and environmental allergies. This novel approach may prevent life-threatening allergic reactions, saving lives and reducing the constant fear that affects millions of people living with severe allergies. SOURCE IgGenix

MicroPharm Limited is pleased to announce that it has been awarded funding from Wellcome to undertake a Phase II clinical trial of an oral therapeutic (OraCAb®) for the treatment of non-life-threatening C. difficile (C. diff.) infection (CDI). OraCAb is a polyclonal antibody-based therapeutic, comprising highly potent antibodies targeting C. diff. toxins and formulated to ensure gut activity. OraCAb was developed in collaboration with the United Kingdom Health Security Agency (UKHSA), Porton Down. MicroPharm will be the Sponsor of the multi-country trial with harmonised trial sites across Kenya and Australia to facilitate assessment of globally circulating C. diff. strains. The Kenyan trial will be undertaken in Nairobi and led by clinicians from the University of Nairobi acting in conjunction with the University of Texas Health Science Center, Houston, USA. The Australian trial will be undertaken by clinicians at the Fiona Stanley Hospital, Perth. C. diff. infection places huge burden on global health systems, is a driver of drug resistance and is the most common cause of infectious diarrhoea in healthcare settings. It is increasingly recognised as a significant cause of diarrhoea in the general community and a major health burden in many Low-and-Middle-Income Countries (LMIC) for example in Kenya where 25% of all patients with diarrhoea are positive for C. diff. toxic strains. It is estimated that in the United States alone, C. diff. accounts for nearly 700,000 infections and 29,000 deaths annually whilst in the UK, there are around 18,000 CDI cases annually with a case fatality rate of around 14%. An affordable and highly effective antibody therapy that has low or minimal risk of developing antimicrobial resistance and is suitable for use in clinical and outpatient settings globally could have huge patient benefit. OraCAb is highly specific in targeting C. diff. toxins TcdA and TcdB and the innovative formulation is designed to maintain OraCAb integrity through the gastrointestinal tract with a view to ensuring activity at the site of C. diff. toxin production. Toxin neutralisation by OraCAb prevents damage to the gut wall and limits disruption to the natural gut flora caused by infection. Importantly, OraCAb offers the potential for global use in neutralising the large variety of 34 different TcdA and TcdB toxinotypes secreted by circulating pathogenic C. diff. strains. A successful trial would demonstrate the power of coupling an antibody platform for oral administration to target enteric and diarrhoeal diseases, paving the way for further development towards treating additional unmet medical need in LMICs such as Shigellosis. Professor John Landon, (MicroPharm Chairman), commented, “We are grateful for Wellcome’s support for this important project, which we believe will be of profound benefit to patients with this globally recognised cause of morbidity and mortality with devastating effects on health-related quality of life. Wellcome Quote: “I’m delighted that Wellcome is investing in the clinical development of OraCAb” said Dr Pete Gardner, Research Lead within Wellcome’s Infectious Disease team. “Supporting the acceleration of new interventions to control infectious disease is critical to Wellcome’s mission and new antibody-based medicines offer a much-needed complementary approach to antibiotics in tackling drug resistant bacterial infections. This partnership with MicroPharm for a Phase II clinical trial is especially exciting as it includes sites in Kenya where OraCAb has the potential to be cost-effective, signalling intent that if shown to be safe and efficacious OraCAb could also be accessible to all who may benefit most from it”.